Overall Survival. (A) OS of the entire cohort. (B) OS of patients with SCID. The Kaplan-Meier survival curve showing that omission of serotherapy leads to excellent OS in patients receiving a fully myeloablative transplant regimen for nonmalignant disorders. OS for the entire cohort was 91% (95% CI, 79-96) at 2 years with OS for SCID patients being 91% (95% CI, 76-97), with a median follow-up of 4.3 years (range, 0.5 to 11 yrs).